Market Overview:
The global systemic infection treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases, rising demand for novel antibiotics and antivirals, and growing awareness about preventive measures against infections. Based on type, the global systemic infection treatment market is segmented into antibacterial, antiviral, and antifungal drugs. Antibacterial drugs are further sub-segmented into beta-lactams, quinolones/fluoroquinolones, tetracyclines/macrolides/chloramphenicol (TETs), aminoglycosides (AGs), glycopeptides (GPs), lincosamides (Lincos), sulfonamides (Sulfas), and other antibacterials. Quinolones/fluoroquinolones are expected to be the fastest-growing sub-segment of antibacterial drugs during the forecast period owing to their high efficacy against various bacterial pathogens. By application, hospitals accounted for the largest share of the global systemic infection treatment market in 2017; however, clinics are projected to be the fastest-growing segment during the forecast period due to rising demand for outpatient services among patients suffering from infectious diseases.
Product Definition:
A systemic infection is an infection that has spread throughout the body. Systemic infections can be serious and may require treatment with antibiotics or other medications.
Antibacterial:
Antibacterial Market Size, Share & Trends Analysis Report By Product (Gram Positive, Gram Negative), By Application (Infectious Diseases, Cardiovascular Disease) And Segment Forecasts To 2020 -> Increasing prevalence of infectious diseases such as HIV/AIDS and cancer is expected to drive the global antibacterial market. Antibiotics are used in both preventive and therapeutic treatments for these diseases. Growing demand for antibiotics in animal feed production is also expected to fuel market growth over the forecast period.
Antiviral:
Antiviral is a medication used to treat viral infections. There are many viruses that cause diseases like influenza, measles, mumps, and chickenpox. Antiviral medications can shorten the duration and lessen the severity of these illnesses. Some antivirals also have the ability to cure them completely.
The global antiviral market size was valued at USD 21 billion in 2016.
Application Insights:
The hospitals segment held the largest share of 60.0% in 2017. The hospitals are considered as the most prominent application for systemic infection treatment as they provide a safe haven for patients with multiple complex diseases and injuries. These types of infections spread rapidly through hospital environments owing to improper hygiene and handling of patients, medical devices, and contaminated surfaces & equipment. As a result, they require an extensive amount of antibiotics to treat them effectively which may increase the risk for antibiotic-resistant bacteria if proper measures are not taken during its administration at appropriate intervals (as prescribed by doctors).
According to a study published in Clinical Infectious Diseases Journal in 2015, it was observed that approximately 50% to 75%of all healthcare-associated infections (HAIs) can be attributed to either human error or environmental contamination which indicates that there is still room for improvement when it comes time treating SSI globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing healthcare expenditure are some of the factors responsible for its dominance. Moreover, rising incidence of multi-drug resistant tuberculosis is expected to drive the demand for GSIT drugs in this region over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to growing penetration of generics and branded generic drugs as well as an increase in public & private healthcare expenditure levels that have resulted from economic growth. Furthermore, countries such as China & India are witnessing a rise in MDR/XDR tuberculosis cases which will further boost revenue generation from 2016 to 2030 in Asia Pacific region due to high unmet needs regarding systemic infections treatment coupled with rapidly improving healthcare infrastructure and low cost structure associated with local production & distribution networks has made it attractive for major pharmaceutical companies including Gilead Sciences Inc.
Growth Factors:
- Increasing incidence of systemic infections: The incidence of systemic infections is increasing at a rapid pace due to the changing lifestyle and environmental conditions. This is propelling the demand for systemic infection treatment products and services, thereby driving the growth of the market.
- Rising awareness about preventive measures: There is a growing awareness among people about preventive measures against systemic infections. This is encouraging them to adopt appropriate preventive measures, which in turn is boosting the demand for system infection treatment products and services.
- Technological advancements: The development of innovative technologies for diagnosis and treatment of system infections has been aiding in their early detection and effective management, thus driving market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Infection Treatment Market Research Report
By Type
Antibacterial, Antiviral, Antifungal
By Application
Hospitals, Clinics, Others
By Companies
Abbott Laboratories, Merck & Co., Pfizer, GlaxoSmithKline, Novartis, Johnson & Johnson, Sun Pharmaceuticals, Roche, Astra Zeneca, Wockhardt, Mylan Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Infection Treatment Market Report Segments:
The global Systemic Infection Treatment market is segmented on the basis of:
Types
Antibacterial, Antiviral, Antifungal
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Merck & Co.
- Pfizer
- GlaxoSmithKline
- Novartis
- Johnson & Johnson
- Sun Pharmaceuticals
- Roche
- Astra Zeneca
- Wockhardt
- Mylan Pharma
Highlights of The Systemic Infection Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibacterial
- Antiviral
- Antifungal
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Infection Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic infection treatment is a combination of antibiotics and other treatments that are used to treat an infection throughout the body. Systemic infections can be difficult to treat, and can lead to serious health problems if not treated quickly.
Some of the key players operating in the systemic infection treatment market are Abbott Laboratories, Merck & Co., Pfizer, GlaxoSmithKline, Novartis, Johnson & Johnson, Sun Pharmaceuticals, Roche, Astra Zeneca, Wockhardt, Mylan Pharma.
The systemic infection treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Systemic Infection Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Systemic Infection Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Systemic Infection Treatment Market - Supply Chain
4.5. Global Systemic Infection Treatment Market Forecast
4.5.1. Systemic Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Systemic Infection Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Systemic Infection Treatment Market Absolute $ Opportunity
5. Global Systemic Infection Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Systemic Infection Treatment Market Size and Volume Forecast by Type
5.3.1. Antibacterial
5.3.2. Antiviral
5.3.3. Antifungal
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Systemic Infection Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Systemic Infection Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Systemic Infection Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Systemic Infection Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Systemic Infection Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Systemic Infection Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Systemic Infection Treatment Demand Share Forecast, 2019-2026
9. North America Systemic Infection Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Systemic Infection Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Systemic Infection Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Systemic Infection Treatment Market Size and Volume Forecast by Type
9.7.1. Antibacterial
9.7.2. Antiviral
9.7.3. Antifungal
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Systemic Infection Treatment Demand Share Forecast, 2019-2026
10. Latin America Systemic Infection Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Systemic Infection Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Systemic Infection Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Systemic Infection Treatment Market Size and Volume Forecast by Type
10.7.1. Antibacterial
10.7.2. Antiviral
10.7.3. Antifungal
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Systemic Infection Treatment Demand Share Forecast, 2019-2026
11. Europe Systemic Infection Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Systemic Infection Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Systemic Infection Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Systemic Infection Treatment Market Size and Volume Forecast by Type
11.7.1. Antibacterial
11.7.2. Antiviral
11.7.3. Antifungal
11.8. Basis Point Share (BPS) Anlysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Systemic Infection Treatment Demand Share, 2019-2026
12. Asia Pacific Systemic Infection Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Systemic Infection Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Systemic Infection Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Systemic Infection Treatment Market Size and Volume Forecast by Type
12.7.1. Antibacterial
12.7.2. Antiviral
12.7.3. Antifungal
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Systemic Infection Treatment Demand Share, 2019-2026
13. Middle East & Africa Systemic Infection Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Systemic Infection Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Systemic Infection Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Systemic Infection Treatment Market Size and Volume Forecast by Type
13.7.1. Antibacterial
13.7.2. Antiviral
13.7.3. Antifungal
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Systemic Infection Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Systemic Infection Treatment Market: Market Share Analysis
14.2. Systemic Infection Treatment Distributors and Customers
14.3. Systemic Infection Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck & Co.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sun Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Roche
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Astra Zeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Wockhardt
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Mylan Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
